-
Something wrong with this record ?
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer
S. Kimura, D. D'Andrea, T. Iwata, B. Foerster, F. Janisch, MK. Parizi, M. Moschini, A. Briganti, M. Babjuk, P. Chlosta, PI. Karakiewicz, D. Enikeev, LM. Rapoport, V. Seebacher, S. Egawa, M. Abufaraj, SF. Shariat
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-02-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-02-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-02-01 to 1 year ago
- MeSH
- Urokinase-Type Plasminogen Activator biosynthesis physiology MeSH
- Plasminogen Activator Inhibitor 1 biosynthesis physiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local epidemiology etiology MeSH
- Biomarkers, Tumor biosynthesis physiology MeSH
- Prostatic Neoplasms epidemiology etiology metabolism surgery MeSH
- Prognosis MeSH
- Prostatectomy * MeSH
- Receptors, Urokinase Plasminogen Activator biosynthesis physiology MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
PURPOSE: To investigate the prognostic role of expression of urokinase-type plasminogen activator system members, such as urokinase-type activator (uPA), uPA-receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). METHODS: Immunohistochemical staining for uPA system was performed on a tissue microarray of specimens from 3121 patients who underwent RP. Cox regression analyses were performed to investigate the association of overexpression of these markers alone or in combination with biochemical recurrence (BCR). Decision curve analysis was used to assess the clinical impact of these markers. RESULTS: uPA, uPAR, and PAI-1 were overexpressed in 1012 (32.4%), 1271 (40.7%), and 1311 (42%) patients, respectively. uPA overexpression was associated with all clinicopathologic characteristics of biologically aggressive PCa. On multivariable analysis, uPA, uPAR, and PAI-1 overexpression were all three associated with BCR (HR: 1.75, p < 0.01, HR: 1.22, p = 0.01 and HR: 1.20, p = 0.03, respectively). Moreover, the probability of BCR increased incrementally with increasing cumulative number of overexpressed markers. Decision curve analysis showed that addition of uPA, uPAR, and PAI-1 resulted in a net benefit compared to a base model comparing standard clinicopathologic features across the entire threshold probability range. In subgroup analyses, overexpression of all three markers remained associated with BCR in patients with favorable pathologic characteristics. CONCLUSION: Overexpression of uPA, uPAR, and PAI-1 in PCa tissue were each associated with worse BCR. Additionally, overexpression of all three markers is informative even in patients with favorable pathologic characteristics potentially helping clinical decision-making regarding adjuvant therapy and/or intensified follow-up.
Department of Gynecology and Gynecologic Oncology Medical University of Vienna Vienna Austria
Department of Urology Jagiellonian University Kraków Poland
Department of Urology Jikei University School of Medicine Tokyo Japan
Department of Urology Kantonsspital Winterthur Winterthur Switzerland
Department of Urology Shariati Hospital Tehran University of Medical Sciences Teheran Iran
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology University of Montreal Health Center Montreal QC Canada
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Klinik für Urologie Luzerner Kantonsspital Lucerne Switzerland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020095
- 003
- CZ-PrNML
- 005
- 20210830101715.0
- 007
- ta
- 008
- 210728s2020 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-019-03038-5 $2 doi
- 035 __
- $a (PubMed)31797075
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Kimura, Shoji $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Jikei University School of Medicine, Tokyo, Japan
- 245 10
- $a Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer / $c S. Kimura, D. D'Andrea, T. Iwata, B. Foerster, F. Janisch, MK. Parizi, M. Moschini, A. Briganti, M. Babjuk, P. Chlosta, PI. Karakiewicz, D. Enikeev, LM. Rapoport, V. Seebacher, S. Egawa, M. Abufaraj, SF. Shariat
- 520 9_
- $a PURPOSE: To investigate the prognostic role of expression of urokinase-type plasminogen activator system members, such as urokinase-type activator (uPA), uPA-receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), in patients treated with radical prostatectomy (RP) for prostate cancer (PCa). METHODS: Immunohistochemical staining for uPA system was performed on a tissue microarray of specimens from 3121 patients who underwent RP. Cox regression analyses were performed to investigate the association of overexpression of these markers alone or in combination with biochemical recurrence (BCR). Decision curve analysis was used to assess the clinical impact of these markers. RESULTS: uPA, uPAR, and PAI-1 were overexpressed in 1012 (32.4%), 1271 (40.7%), and 1311 (42%) patients, respectively. uPA overexpression was associated with all clinicopathologic characteristics of biologically aggressive PCa. On multivariable analysis, uPA, uPAR, and PAI-1 overexpression were all three associated with BCR (HR: 1.75, p < 0.01, HR: 1.22, p = 0.01 and HR: 1.20, p = 0.03, respectively). Moreover, the probability of BCR increased incrementally with increasing cumulative number of overexpressed markers. Decision curve analysis showed that addition of uPA, uPAR, and PAI-1 resulted in a net benefit compared to a base model comparing standard clinicopathologic features across the entire threshold probability range. In subgroup analyses, overexpression of all three markers remained associated with BCR in patients with favorable pathologic characteristics. CONCLUSION: Overexpression of uPA, uPAR, and PAI-1 in PCa tissue were each associated with worse BCR. Additionally, overexpression of all three markers is informative even in patients with favorable pathologic characteristics potentially helping clinical decision-making regarding adjuvant therapy and/or intensified follow-up.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x biosyntéza $x fyziologie $7 D014408
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x epidemiologie $x etiologie $7 D009364
- 650 _2
- $a inhibitor aktivátoru plazminogenu 1 $x biosyntéza $x fyziologie $7 D017395
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a prostatektomie $7 D011468
- 650 _2
- $a nádory prostaty $x epidemiologie $x etiologie $x metabolismus $x chirurgie $7 D011471
- 650 _2
- $a receptory urokinázového aktivátoru plazminogenu $x biosyntéza $x fyziologie $7 D055293
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a aktivátor plasminogenu urokinasového typu $x biosyntéza $x fyziologie $7 D014568
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a D'Andrea, David $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Iwata, Takehiro $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Foerster, Beat $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland
- 700 1_
- $a Janisch, Florian $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Parizi, Mehdi Kardoust $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Teheran, Iran
- 700 1_
- $a Moschini, Marco $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland $u Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Briganti, Alberto $u Urological Research Institute, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Babjuk, Marko $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Chlosta, Piotr $u Department of Urology, Jagiellonian University, Kraków, Poland
- 700 1_
- $a Karakiewicz, Pierre I $u Division of Urology, University of Montreal Health Center, Montreal, QC, Canada
- 700 1_
- $a Enikeev, Dmitry $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Rapoport, Leonid M $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Seebacher, Veronica $u Department of Gynecology and Gynecologic Oncology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Egawa, Shin $u Department of Urology, Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Abufaraj, Mohammad $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology and Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 38, č. 10 (2020), s. 2501-2511
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31797075 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101715 $b ABA008
- 999 __
- $a ok $b bmc $g 1690812 $s 1140541
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 38 $c 10 $d 2501-2511 $e 20191204 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20210728
